Ratings by Evercore ISI (Joshua Schimmer)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/27/2026 | Denali Therapeutics Inc. | DNLI | Maintain | Outperform (N/A) |
|
Details | ||
| 5/30/2025 | Rocket Pharmaceuticals | RCKT | Downgrade | In Line (Outperform) |
2.62 (3.44) |
31.3% | Details | |
| 5/16/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2024 | Rocket Pharmaceuticals | RCKT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2023 | Denali Therapeutics Inc. | DNLI | Maintain | Outperform (N/A) |
|
Details | ||
| 12/22/2022 | Rocket Pharmaceuticals | RCKT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/2/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/26/2022 | Myovant Sciences Ltd. | MYOV | Downgrade | In Line (Outperform) |
26.72 (26.98) |
0.97% | Details | |
| 9/30/2022 | Rocket Pharmaceuticals | RCKT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2022 | Myovant Sciences Ltd. | MYOV | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2022 | Rocket Pharmaceuticals | RCKT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2021 | BioMarin Pharmaceutical Inc. | BMRN | Upgrade | Outperform (In Line) |
77.43 (59.59) |
-23.04% | Details | |
| 12/10/2020 | Rocket Pharmaceuticals | RCKT | Maintain | Outperform (N/A) |
|
Details | ||
| 6/23/2020 | Myovant Sciences Ltd. | MYOV | Maintain | Outperform (N/A) |
|
Details | ||
| 6/1/2020 | Myovant Sciences Ltd. | MYOV | Maintain | Outperform (N/A) |
|
Details | ||
| 4/30/2020 | resTORbio Inc. | TORC | Upgrade | Outperform (In Line) |
1.22 (2.28) |
86.89% | Details | |
| 3/13/2020 | Denali Therapeutics Inc. | DNLI | Upgrade | Outperform (In Line) |
15.01 (23.29) |
55.16% | Details | |
| 3/13/2020 | Inovio Pharmaceuticals | INO | Upgrade | Outperform (In Line) |
8.37 (1.12) |
-86.62% | Details | |
| 3/13/2020 | Denali Therapeutics Inc. | DNLI | Upgrade | Outperform (In Line) |
16.88 (23.29) |
37.97% | Details | |
| 2/3/2020 | bluebird bio | BLUE | Upgrade | Outperform (In Line) |
79.69 (4.97) |
-93.76% | Details | |
| 12/9/2019 | Audentes Therapeutics | BOLD | Downgrade | In Line (Outperform) |
59.25 (2.48) |
-95.81% | Details | |
| 11/19/2019 | Prothena Corp | PRTA | Upgrade | Outperform (In Line) |
10.24 (8.66) |
-15.43% | Details | |
| 11/19/2019 | Clovis Oncology | CLVS | Downgrade | In Line (Outperform) |
7.06 (0.08) |
-98.87% | Details | |
| 11/19/2019 | bluebird bio | BLUE | Downgrade | In Line (Outperform) |
75.00 (4.97) |
-93.37% | Details | |
| 11/19/2019 | Audentes Therapeutics | BOLD | Upgrade | Outperform (In Line) |
25.55 (59.25) |
131.9% | Details | |
| 3/6/2019 | Alnylam Pharmaceuticals | ALNY | Upgrade | Outperform (In Line) |
88.31 (90.89) |
2.92% | Details | |
| 12/4/2018 | Tesaro | TSRO | Downgrade | In Line (Outperform) |
73.50 (74.96) |
1.99% | Details | |
| 10/15/2018 | argenx SE | ARGX | New Coverage | Outperform (N/A) |
72.69 (860.55) |
1083.86% | Details |
